ME03403B - Postupci za povećanje forsiranog ekspiratornog volumena kod asmatičara korišćenjem benralizumaba - Google Patents

Postupci za povećanje forsiranog ekspiratornog volumena kod asmatičara korišćenjem benralizumaba

Info

Publication number
ME03403B
ME03403B MEP-2019-137A MEP2019137A ME03403B ME 03403 B ME03403 B ME 03403B ME P2019137 A MEP2019137 A ME P2019137A ME 03403 B ME03403 B ME 03403B
Authority
ME
Montenegro
Prior art keywords
asmatics
benralizumab
procedures
expiratory volume
forced expiratory
Prior art date
Application number
MEP-2019-137A
Other languages
German (de)
English (en)
French (fr)
Unknown language (me)
Inventor
Christine Ward
Lorin Roskos
Bing Wang
Donald Raible
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ME03403B publication Critical patent/ME03403B/me

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Endocrinology (AREA)
MEP-2019-137A 2013-08-12 2014-08-07 Postupci za povećanje forsiranog ekspiratornog volumena kod asmatičara korišćenjem benralizumaba ME03403B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361864948P 2013-08-12 2013-08-12
PCT/US2014/050119 WO2015023507A2 (en) 2013-08-12 2014-08-07 Methods for increasing forced expiratory volume in asthmatics using benralizumab
EP14836725.3A EP3033104B1 (en) 2013-08-12 2014-08-07 Methods for increasing forced expiratory volume in asthmatics using benralizumab

Publications (1)

Publication Number Publication Date
ME03403B true ME03403B (me) 2020-01-20

Family

ID=52448838

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2019-137A ME03403B (me) 2013-08-12 2014-08-07 Postupci za povećanje forsiranog ekspiratornog volumena kod asmatičara korišćenjem benralizumaba

Country Status (26)

Country Link
US (1) US9441046B2 (https=)
EP (5) EP3033104B1 (https=)
JP (4) JP6746496B2 (https=)
KR (1) KR102337599B1 (https=)
CN (2) CN105451769A (https=)
AU (2) AU2014306959B2 (https=)
BR (1) BR112016002317A8 (https=)
CA (1) CA2917603C (https=)
CY (2) CY1122033T1 (https=)
DK (2) DK3033104T3 (https=)
ES (2) ES2866426T3 (https=)
HK (1) HK1222559A1 (https=)
HR (2) HRP20190920T1 (https=)
HU (2) HUE043497T2 (https=)
LT (2) LT3520811T (https=)
ME (1) ME03403B (https=)
MX (2) MX381102B (https=)
PL (2) PL3520811T3 (https=)
PT (2) PT3520811T (https=)
RS (2) RS58711B1 (https=)
RU (1) RU2703568C2 (https=)
SG (1) SG11201600483QA (https=)
SI (2) SI3033104T1 (https=)
SM (2) SMT201900311T1 (https=)
TR (1) TR201907907T4 (https=)
WO (1) WO2015023507A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2918105C (en) * 2013-08-12 2023-02-28 Medimmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab
CN111617244A (zh) * 2013-08-12 2020-09-04 阿斯特拉捷利康股份公司 使用贝那利珠单抗改善哮喘症状的方法
KR20160061352A (ko) * 2013-10-15 2016-05-31 메디뮨 엘엘씨 벤랄리주맙을 사용하여 만성 폐쇄성 폐 질환을 치료하는 방법
SI3060229T1 (sl) 2013-10-24 2021-11-30 Astrazeneca Ab Stabilne vodne formulacije protiteles
TW202110479A (zh) * 2019-05-16 2021-03-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法
TW202126688A (zh) * 2019-09-27 2021-07-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療遲發性氣喘之方法
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法
WO2026053166A1 (en) * 2024-09-06 2026-03-12 Medimmune Limited Anti-il5r-alpha treatment for acute exacerbations of asthma and copd

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241944C (zh) 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素-5受体α链的抗体
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7404953B2 (en) 2000-02-15 2008-07-29 Kyowa Hakko Kogyo Co., Ltd. Methods using eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
AU2004279740A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Antibody composition specifically binding to IL-5 receptor
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
HUE036885T2 (hu) 2007-05-14 2018-08-28 Astrazeneca Ab Eljárás a bazofil-szint csökkentésére
RU2383345C1 (ru) * 2008-08-07 2010-03-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") Способ лечения больных бронхиальной астмой
TWI732259B (zh) * 2010-12-16 2021-07-01 美商建南德克公司 關於th2抑制作用之診斷及治療
CN102544908B (zh) 2010-12-17 2016-01-06 富士康(昆山)电脑接插件有限公司 电连接器组件及插头连接器
EP2710370A4 (en) 2011-05-18 2015-01-07 Medimmune Llc METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS
HK1201440A1 (en) 2011-11-01 2015-09-04 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma
CA2918105C (en) * 2013-08-12 2023-02-28 Medimmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab
CN111617244A (zh) * 2013-08-12 2020-09-04 阿斯特拉捷利康股份公司 使用贝那利珠单抗改善哮喘症状的方法

Also Published As

Publication number Publication date
SMT202100152T1 (it) 2021-05-07
RU2016108809A (ru) 2017-09-18
WO2015023507A3 (en) 2015-04-09
US9441046B2 (en) 2016-09-13
EP4636400A2 (en) 2025-10-22
CN111588849A (zh) 2020-08-28
CY1122033T1 (el) 2020-10-14
PL3520811T3 (pl) 2021-08-02
CY1124399T1 (el) 2022-07-22
LT3520811T (lt) 2021-03-25
HK1225300A1 (en) 2017-09-08
CA2917603A1 (en) 2015-02-19
RS58711B1 (sr) 2019-06-28
KR102337599B1 (ko) 2021-12-10
EP4579236A2 (en) 2025-07-02
RU2016108809A3 (https=) 2018-06-18
SG11201600483QA (en) 2016-02-26
JP2020125304A (ja) 2020-08-20
HK1222559A1 (zh) 2017-07-07
TR201907907T4 (tr) 2019-06-21
HRP20190920T1 (hr) 2019-07-12
SMT201900311T1 (it) 2019-07-11
EP3875487A1 (en) 2021-09-08
JP2022120010A (ja) 2022-08-17
AU2014306959A1 (en) 2016-02-04
HUE043497T2 (hu) 2019-08-28
DK3033104T3 (da) 2019-06-17
RS61565B1 (sr) 2021-04-29
EP3033104A2 (en) 2016-06-22
CA2917603C (en) 2023-05-16
HRP20210406T1 (hr) 2021-04-30
EP3033104B1 (en) 2019-04-03
ES2866426T3 (es) 2021-10-19
JP6746496B2 (ja) 2020-08-26
JP2024129140A (ja) 2024-09-26
EP4636400A3 (en) 2025-12-24
MX2021003826A (es) 2021-05-27
SI3520811T1 (sl) 2021-04-30
SI3033104T1 (sl) 2019-06-28
DK3520811T3 (da) 2021-03-22
EP3033104A4 (en) 2017-03-22
ES2733602T3 (es) 2019-12-02
WO2015023507A2 (en) 2015-02-19
EP3520811A1 (en) 2019-08-07
EP4579236A3 (en) 2025-09-17
LT3033104T (lt) 2019-06-25
MX381102B (es) 2025-03-12
JP2016527325A (ja) 2016-09-08
WO2015023507A8 (en) 2015-09-24
PT3033104T (pt) 2019-06-27
PT3520811T (pt) 2021-03-15
AU2014306959B2 (en) 2019-11-21
RU2703568C2 (ru) 2019-10-21
HUE053627T2 (hu) 2021-07-28
KR20160043049A (ko) 2016-04-20
CN105451769A (zh) 2016-03-30
MX2016001384A (es) 2016-08-03
AU2020201277A1 (en) 2020-03-12
BR112016002317A2 (pt) 2017-12-12
US20150044203A1 (en) 2015-02-12
EP3520811B1 (en) 2020-12-30
BR112016002317A8 (pt) 2018-06-12
PL3033104T3 (pl) 2019-09-30

Similar Documents

Publication Publication Date Title
IL246002A0 (en) Novel methods
DK3036329T3 (da) Immunonkolytiske terapier
ME03403B (me) Postupci za povećanje forsiranog ekspiratornog volumena kod asmatičara korišćenjem benralizumaba
SI2991633T1 (sl) Terapija za bakteriofagi
UA29750S (uk) Інгалятор
LT3035885T (lt) Inhaliatorius
UY4326S (es) Silla
DK3035886T3 (da) Inhalator
LT3035887T (lt) Inhaliatorius
EP2994184C0 (en) An unravelable catheter
FI20135815L (fi) Teline
EP2975931A4 (en) DEUTERIUM-ENRICHED ALDEHYDE
DOS2013000229S (es) Dulces
GB2510589B (en) Data replication
BR302013002297S1 (pt) Configuração introduzida em bisnaga
BR302013002005S1 (pt) Configuração introduziada em bombona
FI10266U1 (fi) Vaneri
ES1078499Y (es) Cojin perfeccionado
ES1085879Y (es) Estanteria desmontable
ES1079187Y (es) Babero perfeccionado
UA24530S (uk) Манекен
UA29732S (uk) Диван
UA29736S (uk) Диван
UA29737S (uk) Диван
UA29735S (uk) Диван